A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand

Tobacco Control

Volumn 17, Issue 3, 2008, Pages 177-182

  Thavorn, K ^a,b   Chaiyakunapruk, Nathorn ^a,c,d  

^a NARESUAN UNIVERSITY   (Thailand)

^b UNIVERSITY OF TORONTO   (Canada)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE QUALITY; HEART DISEASE; HUMAN; LIFE EXPECTANCY; LUNG TUMOR; MALE; MIDDLE AGED; PHARMACY; PROBABILITY; SMOKING; SMOKING CESSATION; STATISTICS; THAILAND;

ADULT; COMMUNITY PHARMACY SERVICES; COST-BENEFIT ANALYSIS; FEMALE; HEART DISEASES; HUMANS; LIFE EXPECTANCY; LUNG NEOPLASMS; MALE; MARKOV CHAINS; MIDDLE AGED; PROGRAM EVALUATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SMOKING CESSATION; THAILAND;

EID: 45149101022     PISSN: 09644563     EISSN: None     Source Type: Journal    
DOI: 10.1136/tc.2007.022368     Document Type: Article

References (61)

1. US Department of Health and Human Services. The health benefit of smoking cessation: a report of surgeon general. Baltimore, MD: US Department and Healthcare Services, Public Health Service, Center for Diseases Control, 1990.
2. Haustein KO. Tobacco or health. Berlin: Springer-Verlag Berlin Heidelberg, 2003.
3. Peto R. Influence of dose and duration of smoking on lung cancer rate. In: Zaridze, DG, Peto R, eds. Tobacco: a major international health hazard. Lyon: International Agency for Research on Cancer, 1986.
4. Tobacco Control Research and Knowledge Management Center. Survey of cigarettes smoking behavior in Thai population the age of 15 and over. Bangkok: Tobacco Control Research and Knowledge Management Center, 2007.
5. Vateesatokit P. Important smoking statistic of Thai population. Bangkok: ASH Thailand, 2004.
6. Ministry of Public Health. Public health statistics AD 2004. http://203.157.19.191/index-stat47.htm (accessed 9 May 2006).
7. Pongpanich S. A comparative analysis between present and future tobacco related health care costs in Thailand. Bangkok: The College of Public Health, 2003.
8. Fiore MC, Bailey WC, Cohen SJ, et al. Smoking cessation. Rockville, MD: Agency for Health Care Policy and Research, US Department of Health Human Services, 1996.
9. Skaar KL, Tsoh JY, McClure JB, et al. Smoking cessation: 1. An overview of research. Behav Med 1997;23:5-13.
10. Brown RA, Larkin JC, Davis RL. Current concepts in the management of smoking cessation: a review. Am J Managed Care 2000;6:394-404.
11. Cinciripini PM, McClure JB. Smoking cessation -recent developments in behavioral and pharmacologic interventions. Oncology 1998;12:249-56.
12. Parrot S, Godfrey C. The cost-effectiveness of smoking cessation programs. J Clin Psychiatry Monogr 2003;18:50-7.
13. Vitale F. Professional intervention for smoking cessation: the contribution of pharmacist. Eur J Public Health 2000;10:21-4.
14. Parrot S, Godfrey C. Economics of smoking cessation. BMJ 2004;328:947-9.
15. US Public Health Services. Treating tobacco use and dependence. Baltimore, MD: US Public Health Service, 2000.
16. World Health Organization. Policy recommendations on smoking cessation and treatment tobacco dependence. Geneva: WHO, 2003.
17. Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med 2000;346:506-12.
18. Rennard SI, Daughton DM. Smoking cessation. Chest 2000;117:360-4.
19. West R, McNeill A, Raw M. Smoking cessation guidelines for health professional: an update. Thorax 2000;55:987-99.
20. Thananithisak C, Nimpitakpong P. Smoking cessation services in Thailand. 13th World Conference on Tobacco OR Health http://2006.confex.com/ uicc/wctoh/techprogram/P3774.HTM, 2006 (accessed 13 September 2006).
21. Health Education Authority. Health promotion and the community pharmacist. London: HEA, 1994.
22. Thai Pharmacy Network for Tobacco Control Pharmacy Council. Assessment of the efficiency of building Thai Pharmacy Network for Tobacco Control report. Bangkok: PNTC, 2006.
23. McElnay JC, Maguire TA, Drummond A. Smoking cessation: the contribution of community pharmacy. Drugs 2000;8;147-58.
24. Smith MD, McGhan WF, Lauger G. Pharmacist counseling and outcomes of smoking cessation. American Pharmacy 1995;35:20-32.
25. Barbero Gonzalez JA, Quintas Rodriguez AM, Camacho JE. Smoking cessation from the community pharmacy. Atencion Primaria 2000;26:693-6.
26. Zullich AJ, Ryan M, Adams A, et al. Effectiveness of a pharmacist-based smoking cessation program and its impact on quality of life. Pharmacotherapy 2002;22:759-65.
27. Maguire TA, McElnay JC, Drummond A. A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Addiction 2001;96:325-31.
28. Sinclair HK, Bond CM, Lennox AS, et al. An evaluation of a training work shop for community pharmacists and pharmacy assistants based on the stage of change model of smoking cessation. Health Educ J 1997;56:296-312.
29. Williams DM, Newsom JF, Brock TP. An evaluation of smoking cessation-related activities by pharmacists. J Am Pharm Assoc 2000;40:366-70.
30. Crealey GE, McElnay JC, Maguire TA, et al. Costs and effects associated with a community pharmacy-based smoking-cessation programs. Pharmacoeconomics 1998;14:323-33.
31. Sinclair HK, Silcock J, Bond CM, et al. The cost-effectiveness of intensive pharmaceutical intervention in assisting people to stop smoking. Int J Pharm Pract 1999;7:107-12.
32. Tran MT, Holdford DA, Kennedy DT, et al. Modeling the cost-effectiveness of a smoking-cessation program in a community pharmacy practice. Pharmacotherapy 2002;22:1623-31.
33. Roger GR, Powell-Griner E. Life expectancy of cigarette smokers and nonsmokers in the United States. Soc Sci Med 1991;32:1151-9.
34. National Health Statistic Organization. The cigarette smoking and alcoholic drinking behavior survey. Bangkok: National Health Statistic Organization, 2004.
35. Sinclair SK, Bond CM, Stead LF. Community pharmacist personnel interventions for smoking cessation (review). The Cochrane Library 2006 issue 1. http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/ CD003698/frame.html (accessed 15 September 2006).
36. Lindberg A, Jonsson AC, Ronmark E, et al. Ten-year cumulative incidence of COPD and risk factors for incident disease in a symptomatic cohort. Chest 2005;127:1544-52.
37. Haiman C, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006;354:333-42.
38. Johannesson M, Hedbrant J, Jonsson B. A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Linkoping: Centrum for utvardering av medicinsk teknologi (CMT), 1991.
39. The InterASIA Collaborative Group. Cardiovascular risk factor in urban and rural Thailand-The International Collaborative Study of Cardiovascular Disease in Asia. Eur J Cardiovasc Prev Rehabil 2003;10:249-57.
40. Johansson PM. A model for economic evaluation smoking cessation interventions. Stockholm: Stockholm Center for Public Health, Stockholm Country Council, 2004.
41. Menotti A, Blackburn H, Seccareccia F, et al. The relation of chronic diseases to all-cause mortality risk -the Seven Countries Study. Ann Med 1997;29:135-41.
42. Ratanarat P. Survival of patients with lung cancer in Thailand. Bangkok: Master thesis, Mahidol University, 1998.
43. Nanthamongkol S, Chompunuch W, Sirichaiboonwatt S. Costs of smoking cessation service by community pharmacist. Master Independent Study. Phitsanulok: Naresuan University, 2006.
44. Drug and Medical Supply Information Center (DMSIC). The reference costs of national of public health. http://dmsic.moph.go.th/price. htm, 2005 (accessed 23 October 2006).
45. Kanthanraj K. Economic loss assessment of lung cancer caused by smoking. Master thesis. Bangkok: Thammasat University, 1996.
46. Hattapornsawan Y, Saenghirunvattana S, Udomsabpayakul U. The cost of treatment of COPD patients at Ramathibodi Hospital (2000-2001). Int Med J Thailand 2001;17:338-41.
47. Maranetra KN, Chuaychoo B, Dejsomritrutal W, et al. The prevalence and incidence of COPD among older persons of Bangkok metropolis. J Med Assoc Thailand 2002;85:1147-55.
48. Chirakhup S. Estimation of cost data used in CORE Model. Master thesis. Phitsanulok: Naresuan University, 2006.
49. Youngkong S, Riewpaiboon A, Towanabut S, et al. Costs of cerebral infarction in societal perspective. J Pharm Sci 2002;7:95-105.
50. Ministry of Commerce. Report for general consumer price index of Thailand Year 1995-2006 (BASE YEAR 2002). http://www.indexpr.moc.go.th/ price_present/TableIndexG_region_eng.asp (accessed 20 June 2006).
51. Drummond MF, O'Brien B, Stoddart GL, et al. Method for the economic evaluation of health care programs. 2nd ed. New York: Oxford University Press, 1997.
52. Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics. 2nd ed. Cincinnati, OH: Whitney Books Company, 1999.
53. Hunink M, Glasziou P, Siegel J, et al. Decision making in health and medicine: Integrating evidence and values. Cambridge: Cambridge University Press, 2001.
54. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
55. Leu RE, Schaub T. Does smoking increase medical care expenditure? Soc Sci Med 1983;17:1907-14.
56. Leu RE, Schaub T. More on the impact of smoking on medical care expenditure. Soc Sci Med 1985;21:825-7.
57. Oster G, Colditz GA, Kelly NL. The economic costs of smoking and benefit of quitting for individual smokers. Prev Med 1984;13:377- 89.
58. Hodson TA. Cigarette smoking and lifetime medical expenditures. Milbank Q 1992;70:81-124.
59. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, et al. Cost-effectiveness analysis of face-to-face smoking cessation interventions by professional. Rotterdam: Institute for Medical Technology Assessment, 2003.
60. Johansson PM, Tillgren PE, Guldbrandsson KA, et al. A model for cost-effectiveness analyses of smoking cessation interventions applied to a quit-and-win contest for mothers of small children. Scand J Public Health 2005;33:343-52.
61. World Health Organization. Epidemiological and health-economic model for smoking-related morbidity. Geneva: WHO, 2000.